Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains

Executive Summary

Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.

Advertisement

Related Content

Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio
Reckitt At '2.0' On Nutrition Market Expansion But Question No. 1 Remains, Potential Pfizer Consumer Bid?
Reckitt At '2.0' On Consumer Expansion But Question No. 1 Remains, Potential Pfizer Business Bid?
Nutritionals Mean Health Care To Reckitt And A Boon For China Business
Private Label Mucinex March Reaches Two Formulations
Industry Roundup: NJ Limits DXM Sales, RB Out-Licenses K-Y In UK

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123592

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel